Novartis productivity boss seeks procurement's full potential

Novartis' global head of productivity strategy believes the procurement function has become a victim of its own success. While systematically driving cost savings "to impressive results," procurement pros may have built a box around themselves.

Sammy Rashed blogs that execs have become "addicted" to the incremental cost savings delivered courtesy of the procurement office, and they are now unable to imagine any larger role for the function in business success. Undeterred, Rashed has set out from his operational management role with a cohort from finance to "assemble the blueprint for generating...greater productivity" for Novartis while also finding the next horizon for the procurement function. He hopes to move procurement from an agent for growing the bottom line to a force that increases overall operating income.

He promises reports throughout his quest but offers some initial findings. One possibility, he writes, is to improve the demand management process by "combining with such productivity enablers as process reengineering (Six Sigma), allowing the procurement office to work from greater insights than those provided by the traditional method of challenging user requirements and consumption. 

Another early finding: Industry leaders have begun offering integrated end-to-end services solutions. In them, he sees dual benefits of streamlining non-customer-facing processes while offering procurement "a potential career path to [a] board-level position."

- read the blog

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.